After the end of the treatment cycle, the morning and fasting serum was taken to compare and analyze the changes in serum tumor markers CYFRA211, CEA, CA125 and the T lymphocyte subsets CD3+, CD4+, CD8+, CD4+/CD8+ of the two groups of patients. Compare and analyze the changes of the two groups of patients;
At the end of the treatment cycle, serum samples from morning and fasting were collected to analyze the changes of serum tumor markers cyfra211, CEA, CA125, and T lymphocyte subsets CD3 +, CD4 +, CD8 +, CD4 + / CD8 + in the two groups;<br>